The European framework for digital health technology assessment represents a watershed moment for innovation companies seeking reimbursement across fragmented national systems[1][5]. Rather than navigating each country’s unique evaluation pathway from France’s PECAN system to Germany’s DiGA reimbursement model to Belgium’s mHealthBelgium hierarchy, companies can now engage with a harmonised European assessment toolkit designed to translate technical performance into system-legible value propositions[1][5]. This transition matters profoundly because it shifts how health systems interpret whether digital innovations deserve funding, moving away from isolated clinical evidence toward comprehensive real-world value demonstration embedded in operational deployment[4][4].
Understanding the Strategic Shift in Digital Health Evaluation
The EDiHTA consortium launched its call for proposals in March 2026, inviting digital health innovators to participate in pilot implementations across Catalonia and Finland[1]. This initiative is not merely an administrative procedure; it represents the infrastructure through which European healthcare systems will evaluate whether digital diagnostics, digital therapeutics, remote monitoring systems, and AI-assisted clinical tools create genuine value for patients and healthcare budgets. Companies selected for the pilot become reference cases, effectively co-designing how digital innovation will be assessed across EU markets for the next five to ten years[1].
The fundamental problem EDiHTA solves is recognising that digital health innovation in Europe fails not on clinical evidence but on a fragmented interpretation of that evidence[1]. A diagnostic AI system might demonstrate 95 per cent sensitivity in published trials, yet face completely different evaluation standards when seeking reimbursement in Germany, France, Spain, and the United Kingdom. Germany’s DiGA framework emphasises regulatory compliance and software functionality standards[1]. France’s emerging digital health pathways focus on cost-effectiveness relative to standard care[1]. The United Kingdom’s approach through NICE incorporates broader value frameworks that capture societal benefits beyond direct clinical outcomes[1]. Belgium’s mHealthBelgium pyramid assesses technologies through tiered clinical evidence requirements[1]. This fragmentation creates duplication, delays patient access, and forces companies to redesign evidence generation for each market—a process that can extend commercialisation timelines by 18 to 24 months[4][4].
EDiHTA addresses this fragmentation by establishing a common language for how clinical outcomes, patient safety signals, economic impact, and real-world implementation patterns should be structured and presented [1][5]. Rather than asking whether a technology works in controlled conditions, the framework asks whether it changes clinical decisions in actual deployment, what happens to patients as a result, and what financial consequences follow[5]. This distinction is fundamental because it reflects how health systems actually make adoption decisions: they care about evidence proving that procurement will improve outcomes and generate value within their specific resource constraints[4].
Real-World Evidence Infrastructure as Competitive Advantage
Successfully navigating EDiHTA evaluation demands embedding evidence generation into operations from deployment day one, rather than treating evidence collection as an afterthought[4][4]. The most advanced health technology assessment bodies worldwide—including NICE in the United Kingdom, the Canadian Agency for Drugs and Technologies in Health (CADTH), and emerging European agencies have formalised their real-world evidence (RWE) requirements through detailed guidance documents[4][4]. Today, at least 58 separate guidance documents on RWE have been released across fourteen regulatory and HTA agencies globally[4], reflecting the increasing centrality of real-world data to adoption decisions[4].
This infrastructure has three essential components working together. First, standardised data capture protocols ensure that every deployment collects consistent information on diagnostic accuracy, clinician decision patterns, adherence to recommendations, and patient outcomes[4][4]. Rather than allowing sites complete flexibility in what data they collect, sophisticated evidence architecture designates core mandatory data elements that every implementation must capture—such as the presenting clinical question, the system’s recommendation, whether clinicians followed that recommendation, and six-month outcome confirmation[4]. Optional extended datasets based on local capacity might include treatment specifics, additional diagnostic testing, or resource utilisation details. This tiered approach acknowledges that 10-15 per cent of prospective sites will decline participation due to integration burden, yet this attrition is acceptable because standardised implementations create the evidence foundation that drives European adoption[4].
Second, health economics integration transforms raw performance data into procurement-legible narratives[4]. Rather than presenting isolated accuracy metrics, sophisticated evidence demonstrates how the system influences treatment selection, reduces unnecessary testing, improves resource utilisation, and generates cost avoidance[7][8]. For diagnostic systems, this might mean documenting that the technology reduces advanced imaging by 23 per cent of presentations, enables earlier discharge in 19 per cent of imaging-negative cases (reducing average hospital length of stay by 0.8 days), and prevents missed diagnoses in 0.3 per cent of cases[7]. For digital therapeutics, it means tracking engagement dose-response relationships, health outcome improvements measured through validated quality-of-life instruments, and resource utilisation changes such as reduced emergency department visits or hospitalisations[19]. Economic analysis applies established health economics methodologies, including cost-effectiveness analysis using incremental cost-effectiveness ratios (ICERs) relative to standard care, budget impact modelling demonstrating facility-specific cost implications, and cost-utility analysis using quality-adjusted life years (QALYs) or other validated health-state preference measures [25][26].
Third, multi-country evidence architecture prepares simultaneous European expansion[4][4]. Rather than optimising for initial commercial success in the highest-volume market, strategic sequencing prioritises evidence demonstrating transferability across healthcare settings. UK deployments establish scientific rigour through standardised outcome measurement and transparent governance[4]. German implementations demonstrate local applicability within existing DiGA infrastructure and the healthcare system context [1]. Spanish deployments through the Catalan Health Quality Agency (AQuAS) test whether evidence transfers to different patient demographics and healthcare financing models[1]. This sequencing appears slower than revenue-optimised approaches that pursue the highest-volume markets immediately, but it creates the foundation thatEDiHTA evaluation requires: evidence proving that a technology’s value persists across different health systems[4].
The Economics of Real-World Evidence Generation
Health economics now stands as central to digital health adoption rather than peripheral to clinical decisions[1][1]. The traditional model, where companies generate clinical evidence first, then engage health economists to quantify cost-effectiveness, has evolved toward embedding health economics thinking into the initial deployment architecture design[4][4]. This shift reflects how procurement decisions actually occur: health systems increasingly require evidence that expenditure on new technologies generates measurable returns through improved outcomes, reduced costs elsewhere in the system, or both[23][25].
Organisations preparing for the EDiHTA evaluation should understand several key economic frameworks currently guiding HTA decisions[23][25][26]. The cost-effectiveness threshold typically expressed as cost per quality-adjusted life year (QALY) gained—represents the amount a health system considers reasonable to spend for one additional year of perfect health[23]. The United Kingdom’s NICE uses a threshold range of £20,000 to £30,000 per QALY, with provisional higher thresholds for severe conditions[23]. This threshold concept translates technical improvements into financial language procurement teams understand: if your diagnostic system prevents unnecessary advanced imaging and enables faster treatment, the economic value is measurable as cost savings per patient[7][25]. Incremental cost-effectiveness analysis (ICER) compares the additional cost of your technology with its additional health benefit relative to standard care, not in isolation[25]. Budget impact analysis quantifies what procurement will actually cost a specific facility, given its patient volume, case mix, and resource patterns[24]. Cost-utility analysis using QALYs or similar metrics allows comparison across completely different technologies—enabling procurement committees to compare a diagnostic AI system against remote monitoring technology against digital therapeutics on comparable economic grounds [26].
For digital health companies, this means shifting from marketing claims (“our system is 95 percent accurate”) toward economic narratives (“in facilities matching your demographics and resource constraints, procurement generates cost savings of €€15-25 per case through reduced imaging, with 95 percent confidence intervals of X-Y”)[7]. This level of specificity requires embedding health economists into pilot planning, not engaging them retrospectively[4].
Value Demonstration Across Health System Diversity
The European health technology assessment landscape encompasses significant diversity in how different systems define and measure value[14][4]. Some emphasise that clinical effectiveness does the intervention improve patient outcomes compared to standard care[4]? Others prioritise economic efficiency, do benefits justify costs relative to other uses of that funding[23][25]? Still others incorporate broader societal values, including patient experience, equity impacts, and organisational factors[8][14][18]. This diversity means that value demonstration for EDiHTA cannot rely on a single evidence narrative[5].
Rather, successful submissions demonstrate value across multiple dimensions simultaneously[5]. Clinical value is established through real-world outcome data showing whether the technology changes treatment recommendations, whether those changed recommendations improve patient outcomes, and whether improvements persist across different patient populations[5]. Economic value demonstrates cost-effectiveness using established health economics methods, budget impact using facility-specific data, and cost-utility analysis, enabling comparison with other healthcare investments[7][25][26]. Implementation value shows how the technology integrates into existing workflows, what training requirements exist, what cybersecurity considerations matter, and how patient engagement or clinician acceptance influences real-world effectiveness[4][5][20][21]. This multi-dimensional approach is necessary because health systems evaluate technologies through multiple lenses: clinical committees assess medical benefit, procurement evaluates cost-effectiveness, IT assesses security and integration feasibility, and patient representatives increasingly scrutinise equity and access implications[4][5][4][4].
Addressing the Real-World Evidence Harmonization Challenge
While EDiHTA provides a unified framework, it sits within a broader landscape of heterogeneous RWE guidance across regulatory and HTA agencies[4][4][4]. The UK’s MHRA emphasises flexibility and scientific dialogue in RWE evaluation[4]. The European Medicines Agency prioritises consistency and structured governance through detailed methodological requirements[4]. The US FDA provides comprehensive but resource-intensive guidance that reflects extensive documentation requirements and prespecified analytic expectations[4]. This divergence means that companies targeting multiple markets may need to align real-world evidence generation across different standards simultaneously[4][4].
The emerging solution involves what leading agencies call “life-cycle” health technology assessment—where real-world evidence collection continues throughout a product’s commercial life rather than ending at launch[4][4][4]. NICE in the United Kingdom has pioneered this approach through managed access agreements linking reimbursement to ongoing registry data collection[4][4]. Canada and several European agencies have advanced similar frameworks[4][4]. The strategic implication for digital health companies is significant: rather than viewing pilot participation as a discrete research project with defined endpoints, organisations should embed evidence generation as a permanent operational infrastructure[4][4].
Ten Critical Competencies for EDiHTA Success
Understanding Outcome Measurement Hierarchy. EDiHTA evaluation prioritises outcomes that matter to health systems rather than academic metrics alone[1][5]. Diagnostic accuracy (sensitivity/specificity) provides baseline credibility but insufficient evidence for reimbursement[5][7]. Clinical decisions influence whether clinicians actually follow system recommendations and move toward procurement relevance[5]. The impact of patient outcomes on whether changed clinical decisions improve health is essential [7]. Economic consequences, such as cost savings, cost avoidance, and cost-effectiveness, drive procurement decisions[7][25]. Companies should measure and report all four levels, with emphasis on whichever matters most in their specific clinical context[5][7].
Establishing Evidence Operations Governance. Multi-site evidence generation requires dedicated infrastructure separate from clinical operations[4][4]. An evidence operations manager, either internal or contracted, ensures that capture protocols are followed across sites, conducts monthly data quality checks, escalates protocol deviations, and manages site compliance[4][4]. Without this governance, site compliance typically drops below 50 per cent, data quality deteriorates, and the resulting evidence becomes unsuitable for HTA submission[4][4].
Integrating Health Economics Early. Health economists should influence technology design and deployment strategy, not be engaged only when clinical evidence is complete[4][4]. Early integration allows for study design decisions that generate economics-relevant data—such as capturing resource utilisation alongside clinical outcomes, or sequencing deployments to enable budget impact modelling[4][4]. Retrospective health economics often relies on proxy data or modelling assumptions, whereas prospective integration generates direct evidence[25][26].
Designing Registries for Multi-Market Use. Rather than establishing separate research registries, companies should integrate evidence capture into clinical deployment registries used for routine quality monitoring[4][4][4]. This approach reduces site burden, ensures complete data capture, and creates sustainable infrastructure surviving beyond pilot phases[4][4]. Registry design should accommodate different data models and IT infrastructures across European sites, recognising that some will integrate through HL7 interfaces while others require manual data entry[4][4].
Sequencing Deployments Strategically. Geographic sequencing affects evidence transferability and subsequent approval timelines[4][4]. UK deployments establish rigour and transparency appreciated by all European agencies[4]. German implementations demonstrate DiGA compatibility and applicability to the German healthcare system[1]. Spanish or French deployments test evidence transfer across different healthcare financing models[1][4]. This sequencing appears slower than pursuing all markets simultaneously but compresses multi-country approval timelines[4].
Establishing Health Equity Considerations. Leading HTA agencies increasingly require evidence demonstrating that technologies benefit diverse patient populations and do not exacerbate health inequities[4][5][4]. This means ensuring pilot sites include different patient demographics, capturing outcomes stratified by age, sex, socioeconomic status, and clinical complexity, and demonstrating that benefits persist across subgroups[4][5][4].
Building Cybersecurity and Data Governance Credibility. For digital health technologies, cybersecurity and data protection are necessary conditions for reimbursement, not optional features[4][5]. Companies should document compliance with GDPR, establish data governance frameworks demonstrating appropriate access controls, and address privacy considerations in pilot planning[4][5]. European agencies increasingly scrutinise these dimensions because healthcare regulators prioritise patient data protection alongside clinical effectiveness[4][5].
Creating Procurement-Ready Economic Narratives. Rather than presenting generic economic projections, evidence should quantify facility-specific value propositions[7][25]. Example language might read: “In your facility treating 350 cases monthly with demographics matching our deployed sites (63 percent age 18-65, 28 percent age 66+, typical complexity distribution), we project 95.5 percent sensitivity with 95 percent confidence interval 94.2-96.8 percent, with decision influence in 58-62 percent of presentations and 11-minute average emergency department turnaround improvement based on evidence from comparable facilities”[7][25]. This contextual specificity makes evidence credible to procurement teams evaluating local business cases[7][25].
Preparing for Outcome-Based Reimbursement Negotiation. Evidence demonstrating cost avoidance or outcome improvement creates a foundation for reimbursement models shifting from fixed commodity pricing toward performance-based compensation[7][25]. Rather than charging €30 per case, outcome-based structures might charge a €50 baseline plus €15-25 upside if cost avoidance or outcome improvement exceeds defined thresholds[7]. This requires embedding outcome measurement into operational contracts rather than treating it as a research activity[7][25].
Maintaining Transparency Throughout Evaluation. HTA bodies and procurement teams increasingly value transparency in study design, data governance, conflict-of-interest disclosure, and result reporting[4][4][4]. Companies should adopt pre-registration of evaluation protocols, transparent reporting of all outcome metrics (including those showing neutral or negative results), and clear conflict-of-interest disclosures[4][4][4]. This transparency builds credibility essential for reimbursement approval[4][4][4].
Positioning Within Emerging European Digital Health Pathways
EDiHTA should not be positioned as replacing national frameworks, but rather as creating evidence to support expedited approval within existing structures[1][5]. Germany’s DiGA pathway will increasingly recognise devices that have undergone standardised European evaluation[1]. France’s emerging digital health funding mechanisms will incorporate evidence architectures aligned with EDiHTA principles[1]. The United Kingdom’s approach through NICE will accept evidence demonstrating transparent, systematic evaluation aligned with NICE’s real-world evidence framework[4]. Rather than claiming universal applicability, companies should demonstrate contextual applicability: “We have undergone standardised European evaluation; here is how that evidence supports your local approval process”[1][5].
Conclusion
EDiHTA represents a critical inflection point where European health systems move toward harmonised evaluation of digital health technologies while preserving regional flexibility in adoption decisions[1][4][5][4]. For companies developing digital diagnostics, digital therapeutics, remote monitoring systems, or AI-assisted clinical tools, pilot participation offers an unprecedented opportunity to influence how European markets will evaluate innovation over the coming decade[1][5]. Success requires embedding real-world evidence infrastructure into operations from deployment day one, establishing health economics partnerships capable of translating technical performance into procurement-legible value propositions, and sequencing multi-country deployments strategically to demonstrate evidence transferability[4][4][25].
The companies that engage thoughtfully with EDiHTA will emerge as reference cases for how digital innovation reaches European patients and healthcare systems. This is not simply about undergoing evaluation it is about helping define what successful evaluation looks like[1][5].
Frequently Asked Questions (FAQ)
What exactly is EDiHTA and why should my company care about it?
EDiHTA is the European Digital Health Technology Assessment consortium establishing the first pan-European framework for evaluating digital health technologies[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment). Rather than navigating fragmented national approval systems across Germany, France, Spain, and the UK separately, companies can now engage with a harmonised evaluation toolkit. This matters because it compresses reimbursement timelines by 60 percent, reduces evidence generation costs, and positions early participants as reference cases for how European markets will evaluate digital innovation for the next five to ten years[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/).
What is the current deadline for EDiHTA pilot participation?
The application deadline for EDiHTA pilot participation was March 20, 2026 at 3:00 PM Paris time[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment). If this deadline has passed, organisations should contact the EDiHTA consortium directly regarding rolling applications or future pilot phases. Pilot project implementation runs from July 2026 through April 2027[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment).
Who is eligible to apply for EDiHTA pilot participation?
EDiHTA pilot participation is open to startups, small and medium-sized enterprises (SMEs), and large companies established in European Union Member States or countries associated with Horizon Europe[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment). The initiative welcomes developers and manufacturers of digital health technologies including digital therapeutics, diagnostic AI systems, remote monitoring platforms, and other digital health innovations[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment).
How much investment is required to establish EDiHTA-ready infrastructure?
Organisations deploying EDiHTA-ready evidence infrastructure typically invest €400,000 to €600,000 annually during the operational phase (months 10-18), with higher upfront costs during initial design and IT integration phases[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/). This investment covers evidence operations management, health economics partnerships, registry infrastructure, and outcome tracking systems. However, companies embedding evidence generation into commercial operations from deployment day one compress procurement timelines by 60 percent, achieve 75-85 percent HTA approval rates, and unlock outcome-based reimbursement commanding 1.5-2x pricing premiums, making this infrastructure investment a commercial accelerator rather than overhead[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/).
What outcome metrics matter most in EDiHTA evaluation?
EDiHTA assessment moves beyond traditional clinical metrics like sensitivity and specificity to capture what healthcare systems actually prioritise: clinical decision influence (whether clinicians follow system recommendations), patient outcome impact (whether changed recommendations improve health), and economic value (cost savings, cost avoidance, or cost-effectiveness)[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment)[[[5]](https://xtensio.com/frequently-asked-questions-template/)](https://pubmed.ncbi.nlm.nih.gov/41797475/). For diagnostic systems, this means documenting not just accuracy but whether system recommendations change treatment decisions and whether those changes lead to better patient outcomes. For digital therapeutics, it means tracking engagement patterns, dose-response relationships, health outcome improvements measured through validated instruments, and resource utilisation changes[[19]](https://pubmed.ncbi.nlm.nih.gov/41787047/). The strongest submissions quantify all three dimensions through structured real-world deployment data[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment)[[[5]](https://xtensio.com/frequently-asked-questions-template/)](https://pubmed.ncbi.nlm.nih.gov/41797475/).
How should we sequence deployments across different European countries?
Strategic deployment sequencing accelerates European approval significantly more than simultaneous high-volume expansion[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/). Phase one should target UK and Germany (months 1-9): UK deployments establish scientific rigour through standardised outcome measurement appreciated by all European agencies, while German implementations demonstrate local applicability within existing DiGA infrastructure. Phase two involves commercial integration and evidence operations establishment (months 10-18). Phase three deploys across one to two additional European systems such as France or Spain to document evidence transferability (months 15-24). This sequencing appears slower than revenue-optimised approaches pursuing highest-volume markets immediately, but it prepares simultaneous multi-country expansion because evidence proving transportability across different health systems creates the foundation EDiHTA evaluation requires[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/).
How does EDiHTA relate to existing national frameworks like Germany’s DiGA?
EDiHTA should not be positioned as replacing national frameworks but rather as creating evidence that supports expedited approval within existing structures[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment)[[[5]](https://xtensio.com/frequently-asked-questions-template/)](https://pubmed.ncbi.nlm.nih.gov/41797475/). Germany’s DiGA pathway will increasingly recognise devices that have undergone standardised European evaluation. Rather than claiming universal applicability, companies should demonstrate contextual applicability: “We have undergone standardised European evaluation; here is how that evidence supports your local DiGA approval process”[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment). This positioning creates a bridge between European-level evidence and national-level reimbursement decisions[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/).
What role do health economists play in EDiHTA success?
Health economics integration is foundational to transforming technical performance into reimbursement-eligible evidence[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/). Effective partnerships address cost-effectiveness analysis using incremental cost-effectiveness ratios (ICERs) relative to standard care, budget impact analysis quantifying facility-specific cost implications, cost-utility analysis using quality-adjusted life years (QALYs), and outcome-based contract structuring[[7]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12984165/)[[[25]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12971134/)](https://www.youtube.com/watch?v=YmgDg6JF_Fc). Rather than presenting generic economic projections, health economics expertise translates deployment data into facility-specific projections. Health economists should be embedded into pilot planning from the beginning, not engaged retrospectively[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/).
Can we transition from commodity pricing to outcome-based reimbursement using EDiHTA evidence?
Yes, but it requires evidence demonstrating that your system generates measurable value beyond the purchase price[[7]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12984165/). Rather than charging €30 per case as standard commodity pricing, outcome-based structures might charge €50 baseline plus €15-25 performance upside if cost avoidance or outcome improvement exceeds defined thresholds[[7]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12984165/). This pricing migration demands two prerequisites: first, deployment evidence clearly quantifying cost avoidance or outcome improvement; second, contractual structures embedding outcome measurement as reimbursement condition rather than research activity. The economic value proposition must be quantifiable and auditable[[7]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12984165/).
What should we communicate to procurement teams about EDiHTA participation?
Procurement officers increasingly recognise that EDiHTA participation signals evidence quality and market readiness[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment). Your communication should emphasise three elements: first, that pilot participation demonstrates commitment to transparency and standardised evaluation; second, that EDiHTA-compliant data will accelerate subsequent approval timelines and support reimbursement decisions; third, that deployment participation generates facility-specific outcome evidence supporting local business cases[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment)[[[5]](https://xtensio.com/frequently-asked-questions-template/)](https://pubmed.ncbi.nlm.nih.gov/41797475/). Rather than framing pilot participation as research burden, position it as market access enablement. Procurement teams want technologies with clear evidence of value, standardised evaluation demonstrating that value, and established pathways to reimbursement[[1]](https://www.ispor.org/heor-resources/heor-by-topic-new/health-technology-assessment).
How does real-world evidence differ from traditional randomised controlled trial evidence?
Traditional randomised controlled trials generate highly controlled evidence under ideal conditions with selected patient populations, while real-world evidence captures how technologies perform across diverse patient populations, different clinical settings, and actual implementation contexts[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/). EDiHTA prioritises real-world evidence because health systems care about actual performance in their specific contexts, not theoretical performance in ideal conditions[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/). Real-world evidence demonstrates whether clinical decision changes persist when clinicians have full autonomy, whether outcomes vary across different patient demographics, and what implementation barriers exist in actual deployment[[4]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976637/).
References
[1] Cochard, S. (2026, March 17). A call for proposals to establish the European framework for health technology assessment. Health Technology Assessment News.
[5] International Journal of Technology Assessment in Health Care. (2026, March 9). Frameworks for assessing digital health technologies: a scoping review, 42(1):e24.
[7] Cost-effectiveness analysis of AI-assisted breast cancer screening. PMC NIH, 2026. Singapore-specific health economic modelling demonstrating ICER and cost-utility methodology.
[8] National Academies of Sciences, Engineering, and Medicine. (2026). Toward a National Health Digital and Data Architecture. Case studies on the economic impact of digital health across cardiovascular disease, maternal health, and diabetes management.
[19] Schmidt, L., et al. (2026). Mechanisms of action for digital therapeutics. NPJ Digital Medicine, March 5, 2026.
[20] SNS Insider. (2026). Remote Patient Monitoring Market Size & Forecast 2033. Valued at USD 39.97B in 2025, projected USD 103.95B by 2033.
[21] Wearable technology in emergency care. (2026). PMC NIH. Scoping review on wearable applications in emergency medical services and health outcomes.
[23] Barham, L. (2024, December). NICE contribution to the cost per QALY threshold debate. PharmaphForum. Analysis of NICE’s £20,000-£30,000 per QALY threshold and emerging evidence on appropriate cost-effectiveness benchmarks.
[24] ISPOR. (2026, March 25). Primer on a 6-Step Approach to Budget Impact Analysis. Technical methodology for estimating budget impact in healthcare procurement decisions.
[25] HEOR Insights. (2026, March 1). What is ICER? Understanding Incremental Cost-Effectiveness Ratio. Fundamental health economics concepts for non-specialists.
[26] Nielsen, J.S., et al. (2026). Valuing Mortality Risk Reductions and Health Improvements. PMC NIH. Theoretical framework connecting value per statistical life, value per life year, and willingness-to-pay for QALYs.